Abstract
Soft-tissue sarcomas (STSs) has been treated with similar patterns of care but represent an heterogeneous group of diseases. Recently new drugs came out with specific interest for selected histotype STSs. The primary aim of this retrospective study was to describe the outcome, prognostic factors and treatment for patients with metastatic synovial sarcoma (SS) included in the French NETSARC database.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
